Skip to main content
Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.560
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:30 PM EDT

Lineage Cell Therapeutics Revenue

In the year 2025, Lineage Cell Therapeutics had annual revenue of $14.56M with 53.24% growth. Lineage Cell Therapeutics had revenue of $6.61M in the quarter ending December 31, 2025, with 130.40% growth.

Revenue (ttm)
$14.56M
Revenue Growth
+53.24%
P/S Ratio
26.87
Revenue / Employee
$189,039
Employees
77
Market Cap
388.58M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202514.56M5.06M53.24%
Dec 31, 20249.50M554.00K6.19%
Dec 31, 20238.95M-5.76M-39.16%
Dec 31, 202214.70M10.36M238.70%
Dec 31, 20214.34M2.52M137.73%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Puma Biotechnology 228.37M
Vanda Pharmaceuticals 216.11M
Niagen Bioscience 129.42M
Century Therapeutics 109.16M
Autolus Therapeutics 75.39M
Enanta Pharmaceuticals 66.98M
Invivyd 53.43M
X4 Pharmaceuticals 35.11M
Revenue Rankings

LCTX News

More News